Table 1 Recurrent thrombosis in the patients with antiphospholipid antibodies
From: Controversies in the antiphospholipid syndrome: can we ever stop warfarin?
Study design | N | Mean age Years | Entry criteria | Patient Characteristics | Mean Follow up Years | Patients with recurrent events No. (%) | Number of recurrent events All (arterial/venous) | Reference |
|---|---|---|---|---|---|---|---|---|
Retrospective | 70 48W 22M | 45.5 ± 17.3 | aPL (aCL/LA) + arterial/venous thrombosis (1st event) | PAPS 51 SLE 14 ITP 5 | 5.2 | 37/70 (53%) | 54 | Rosove MH et al. Ann Intern Med 1992 |
Retrospective | 19 16W 3M | 26 (15–40) | aPL (aCL/LA) + venous thrombosis (1st event) | PAPS 1 SLE 12 Lupus like 6 | 8 | 12/19 (63%) | 37 (3/34) | Derksen R et al. Ann Rheum Dis 1993 |
Retrospective | 147 124W 23M | 32 (14–66) | aPL (aCL/LA) + arterial/venous thrombosis (1st event) | PAPS 62 SLE 66 Lupus like 19 | 7 | 101/147 (69%) | 186 (75/111) | Khamashta M et al. N Eng J Med 1995 |
Prospective | 360 242W 118M | 39 (2–78) | aPL (aCL/LA) (117 aPL pt with previous arterial/venous thrombosis) | SLE 69 Lupus like 66 | 4 | 25/117 (21.3%) | 25 | Finazzi G et al. Am J Med 1996 |
Prospective | 412 181W 231M | 60.2 | Venous thrombosis (1st event) allocated 6 months warfarin | - | 4 | 20/68 aCL+ (29%) 47/344 aCL- (14%) | 67 (-/67) | Schulman S et al. Am J Med 1998 |
Prospective | 56 48W 8M | 37 ± 10 | APS (aPL + thrombosis and/or fetal loss) (43 patients with previous arterial/venous thrombosis) | PAPS only | 5 | 14/43 (32.5) | 16 (10/6) | Turiel M et al. Stroke 2005 |